Although STAT3 activation in tumor cells is often (though not always) catalyzed by Jak family members, and Jak inhibitors may be effective at suppressing the activating tyrosine phosphorylation of STAT3, there are several reasons why Jak inhibitors may not provide much therapeutic benefit and may even have detrimental effects when used for cancer therapy. This evidence concerns the gene STAT3 and cancer.